The Medicines For All Institute (M4ALL)

In September 2018, we signed a MoU with the Medicines For All Institute (M4ALL) to accelerate access to global health medicines in LMICs, by promoting the reduced cost of active pharmaceutical ingredients (APIs) – a major cost driver in treating infectious diseases in the developing world.